BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi Y, Zheng H, Wang M, Ding S. Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention. Helicobacter 2022;27:e12878. [PMID: 35112435 DOI: 10.1111/hel.12878] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Han Z, Li Y, Li Y. Helicobacter pylori, gastrointestinal microbiota, and immunotherapy. Helicobacter 2023;28:e12942. [PMID: 36478623 DOI: 10.1111/hel.12942] [Reference Citation Analysis]
2 Zhu Y, Zhu F, Ba H, Chen J, Bian X. Helicobacter pylori infection and PD-L1 expression in gastric cancer: A meta-analysis. Eur J Clin Invest 2023;53:e13880. [PMID: 36164962 DOI: 10.1111/eci.13880] [Reference Citation Analysis]
3 Deng R, Zhang H, Li Y, Shi Y. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis. J Immunother 2023;46:43-55. [PMID: 36301729 DOI: 10.1097/CJI.0000000000000442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shi Y, Zheng H, Guo Z, Deng R, Yu W, Song Y, Ding S. Effect of Helicobacter pylori on immunotherapy is gaining more attention. Helicobacter 2022;27:e12925. [PMID: 36036113 DOI: 10.1111/hel.12925] [Reference Citation Analysis]
5 Hu Y, Zhuang Y, Gou H, Xie C, Ge Z. Editorial: The interactions between gastrointestinal microbiota and Helicobacter pylori in diseases. Front Cell Infect Microbiol 2022;12:1043906. [DOI: 10.3389/fcimb.2022.1043906] [Reference Citation Analysis]
6 Agnarelli A, Vella V, Samuels M, Papanastasopoulos P, Giamas G. Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. Cancers 2022;14:4378. [DOI: 10.3390/cancers14184378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Deng R, Zheng H, Cai H, Li M, Shi Y, Ding S. Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. Front Immunol 2022;13:923477. [DOI: 10.3389/fimmu.2022.923477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Oster P, Vaillant L, Mcmillan B, Velin D. The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection. Front Immunol 2022;13:899161. [DOI: 10.3389/fimmu.2022.899161] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]